Literature DB >> 26061605

An Inverse Relationship Between Weight and Free Thyroxine During Early Gestation Among Women Treated for Hypothyroidism.

James E Haddow1,2, Louis M Neveux1,2, Glenn E Palomaki1,2, Geralyn Lambert-Messerlian1, Fergal D Malone3,4, Mary E D'Alton3.   

Abstract

BACKGROUND: Following treatment sufficient to normalize thyrotropin (TSH), nonpregnant hypothyroid adults display higher free thyroxine (FT(4)) concentrations than a reference population. Our aim is to determine whether FT(4) concentrations are higher during pregnancy among women treated for hypothyroidism and whether their weight is associated with FT(4) levels. Weight/FT(4) relationships have not previously been reported in treated hypothyroid adults (either pregnant or nonpregnant).
METHODS: Thyroid-related measurements were available from over 10,000 women at two early pregnancy time periods from the FaSTER (First and Second Trimester Evaluation of Risk for Fetal aneuploidy) trial (1999-2002). All women were receiving routine prenatal care. Present analyses were restricted to 9267 reference women and 306 treated, hypothyroid women with TSH between the 2nd and 98th reference percentiles. We compared FT(4) values between those groups at 11-14 and 15-18 weeks' gestation, using linear regression to estimate FT(4)/maternal weight relationships, after accounting for treatment and other potential covariates.
RESULTS: In comparison to reference women, median FT(4) values and percent of FT(4) values ≥95th reference percentile were significantly higher in treated women at both 11-14 and 15-18 weeks' gestation (p<0.001) overall and after stratification by weight into tertiles. Among both treated and reference women, median FT(4) decreased monotonically with increasing weight, regardless of anti-thyroperoxidase antibody status. Maternal age, maternal weight, and treatment status were important predictors of FT(4) levels (p<0.001, defined by partial r(2) values of 1% or higher). Anti-thyroperoxidase antibody status, TSH values (after logarithmic transformation), and all interaction terms were well below an r(2) of 1%. FT(4) levels were 1.45 pmol/L higher in treated than reference women, independent of other factors. Maternal age and weight reduced FT(4) levels by 0.0694 pmol/L/y and 0.0208 pmol/L/kg, respectively.
CONCLUSIONS: FT(4) concentrations are higher among treated hypothyroid pregnant women than among reference women, and higher maternal weight is associated with lower FT(4) levels, regardless of treatment status. This inverse relationship is not associated with higher TSH levels. While no immediate clinical implications are attached to the current observations, increased peripheral deiodinase activity in the presence of higher weight might explain these findings. Further investigation appears worthy of attention.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26061605      PMCID: PMC4533030          DOI: 10.1089/thy.2015.0085

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  20 in total

1.  Sequential first- and second-trimester TSH, free thyroxine, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER trial study.

Authors:  Monica R McClain; Geralyn Lambert-Messerlian; James E Haddow; Glenn E Palomaki; Jacob A Canick; Jane Cleary-Goldman; Fergal D Malone; T Flint Porter; David A Nyberg; Peter Bernstein; Mary E D'Alton
Journal:  Am J Obstet Gynecol       Date:  2008-04-29       Impact factor: 8.661

2.  Serum free thyroxine concentration is associated with metabolic syndrome in euthyroid subjects.

Authors:  Ladan Mehran; Atieh Amouzegar; Maryam Tohidi; Maryam Moayedi; Fereidoun Azizi
Journal:  Thyroid       Date:  2014-09-26       Impact factor: 6.568

3.  TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy.

Authors:  Mitsuru Ito; Akira Miyauchi; Shinji Morita; Takumi Kudo; Eijun Nishihara; Minoru Kihara; Yuuki Takamura; Yasuhiro Ito; Kaoru Kobayashi; Akihiro Miya; Sumihisa Kubota; Nobuyuki Amino
Journal:  Eur J Endocrinol       Date:  2012-06-18       Impact factor: 6.664

4.  Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations.

Authors:  K A Woeber
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

5.  Triiodothyronine levels in athyreotic individuals during levothyroxine therapy.

Authors:  Jacqueline Jonklaas; Bruce Davidson; Supna Bhagat; Steven J Soldin
Journal:  JAMA       Date:  2008-02-20       Impact factor: 56.272

6.  Chemical hyperthyroidism: serum triiodothyronine levels in clinically euthyroid individuals treated with levothyroxine.

Authors:  D Salmon; M Rendell; J Williams; C Smith; D A Ross; J M Waud; J E Howard
Journal:  Arch Intern Med       Date:  1982-03

7.  First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study.

Authors:  Geralyn Lambert-Messerlian; Monica McClain; James E Haddow; Glenn E Palomaki; Jacob A Canick; Jane Cleary-Goldman; Fergal D Malone; T Flint Porter; David A Nyberg; Peter Bernstein; Mary E D'Alton
Journal:  Am J Obstet Gynecol       Date:  2008-07       Impact factor: 8.661

8.  Using body mass index to predict optimal thyroid dosing after thyroidectomy.

Authors:  Kristin A Ojomo; David F Schneider; Alexandra E Reiher; Ngan Lai; Sarah Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  J Am Coll Surg       Date:  2013-01-11       Impact factor: 6.113

9.  Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans.

Authors:  L H Fish; H L Schwartz; J Cavanaugh; M W Steffes; J P Bantle; J H Oppenheimer
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

10.  Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients.

Authors:  Damiano Gullo; Adele Latina; Francesco Frasca; Rosario Le Moli; Gabriella Pellegriti; Riccardo Vigneri
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

View more
  5 in total

1.  Free Thyroxine During Early Pregnancy and Risk for Gestational Diabetes.

Authors:  James E Haddow; Wendy Y Craig; Louis M Neveux; Glenn E Palomaki; Geralyn Lambert-Messerlian; Fergal D Malone; Mary E D'Alton
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

2.  Reference Intervals of Thyroid Hormones and Correlation of BMI with Thyroid Function in Healthy Zhuang Ethnic Pregnant Women.

Authors:  Yonghong Sheng; Dongping Huang; Shun Liu; Xuefeng Guo; Jiehua Chen; Yantao Shao; Guoqiang Zhang; Liangjia Wei; Xiaoyun Zeng; Xiaoqiang Qiu
Journal:  Biomed Res Int       Date:  2018-11-14       Impact factor: 3.411

Review 3.  Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults.

Authors:  Philippe Caron; Solange Grunenwald; Luca Persani; Françoise Borson-Chazot; Remy Leroy; Leonidas Duntas
Journal:  Rev Endocr Metab Disord       Date:  2021-10-20       Impact factor: 9.306

4.  Peripheral deiodinase activity: A potential explanation for the association between maternal weight and gestational hyperglycemia.

Authors:  James E Haddow; Geralyn Lambert-Messerlian; Elizabeth Eklund; Louis M Neveux; Glenn E Palomaki
Journal:  Obstet Med       Date:  2017-10-12

5.  Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters.

Authors:  Bridget A Knight; Beverley M Shields; Andrew T Hattersley; Bijay Vaidya
Journal:  Eur J Endocrinol       Date:  2016-01       Impact factor: 6.664

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.